Additionally, Gzma–/– T cell recipients had similar frequencies of GFP+ tumor cells in the bone marrow (P > 0.05) and only modestly increased mortality due to leukemia (42%, P > 0.05 as compared with WT allo-HCT recipients; Figure 8, A–D). The gene discussed is GZMA; the disease is neoplasm.